Prevail Therapeutics Inc

Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.

NEW YORK, Dec.  26, 2019  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has notified Prevail that the Company’s Investigational New Drug (IND) application for PR001 for the treatment of neuronopathic Gaucher disease (nGD) patients is now active and that Prevail may proceed with initiating its proposed clinical trial. As previously reported, Prevail’s IND for PR001 for the treatment of nGD had been put on clinical hold by the FDA, and this clinical hold has now been removed.

Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease

Prevail Therapeutics Inc. (NASDAQ: PRVL) shares jumped early on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation (ODD) for its dementia treatment.

Will This Dementia Treatment Be a Big Hit After FDA Decision?

NEW YORK, Dec.  16, 2019  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation (ODD) for the company’s gene therapy candidate, PR006, for the treatment of patients with frontotemporal dementia (FTD) with a GRN mutation (FTD-GRN). PR006 is designed to increase progranulin levels in FTD-GRN patients by delivering a healthy GRN gene using an AAV9 vector.

Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation

NEW YORK, Nov.  18, 2019  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of Morgan Sheng, Ph.D., to its Board of Directors.

Prevail Therapeutics Announces Appointment of Morgan Sheng, Ph.D., to Board of Directors

Strategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients with neurodegenerative diseases

Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases

NEW YORK, Oct.  01, 2019  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that management will present at three upcoming conferences in October:

Prevail Therapeutics to Present at Upcoming October Conferences

NEW YORK, Sept.  19, 2019  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that it will be added to the Russell 2000 and Russell 3000 and Microcap Indexes, effective after the close of the U.S. markets on Friday, September 20, 2019.

Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® Indexes

NEW YORK, Sept.  10, 2019  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ: PRVL), a biotechnology company developing AAV-based gene therapies for patients with neurodegenerative disorders, today provided an update on the Company’s clinical development of PR001, a potentially disease-modifying, single-dose gene therapy in development for Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD).

Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease

NEW YORK, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will present at the Morgan Stanley 2019 Global Healthcare Conference on Wednesday, September 11, 2019 at 1:00 p.m. ET in New York City.

Prevail Therapeutics to Present at Morgan Stanley 2019 Global Healthcare Conference

Prevail Therapeutics Inc (NASDAQ: PRVL) shares traded higher on Monday after a pair of Wall Street analyst initiated bullish coverage of the stock.

Analysts Initiate Bullish Coverage Of Prevail Therapeutics

Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher after the company received FDA fast track designation for PR001 for the treatment of Parkinson's disease patients with a GBA1 mutation.

FDA Grants Fast Track Designation For Prevail's Parkinson's Treatment

New York-based Prevail Therapeutics opened for trade Thursday afternoon at $15.31 per share.

News for Prevail Therapeutics Inc Stock (PRVL)